Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in MSI-H/dMMR Solid Tumors
CTR20200184Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Feb 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Feb 2020; status: terminated.
02
Drugs
cadonilimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20200184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200184.